Abstract | OBJECTIVE: CASE SUMMARY: DISCUSSION: CONCLUSIONS: This interaction between TMP/SMX and repaglinide may have involved inhibition of CYP2C8 by trimethoprim. Clinicians should be aware that this association may lead to symptomatic hypoglycemia, particularly in patients with renal dysfunction.
|
Authors | Matthieu Roustit, Emeline Blondel, Céline Villier, Xavier Fonrose, Michel P Mallaret |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 44
Issue 4
Pg. 764-7
(Apr 2010)
ISSN: 1542-6270 [Electronic] United States |
PMID | 20197475
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Anti-Infective Agents, Urinary
- Blood Glucose
- Carbamates
- Hypoglycemic Agents
- Piperidines
- repaglinide
- Trimethoprim, Sulfamethoxazole Drug Combination
|
Topics |
- Aged
- Anti-Infective Agents, Urinary
(adverse effects)
- Blood Glucose
(metabolism)
- Carbamates
(adverse effects)
- Diabetes Complications
(chemically induced)
- Diabetes Mellitus
(blood, drug therapy)
- Diabetic Neuropathies
(complications)
- Drug Interactions
- Energy Intake
- Humans
- Hypoglycemia
(chemically induced)
- Hypoglycemic Agents
(adverse effects)
- Male
- Piperidines
(adverse effects)
- Trimethoprim, Sulfamethoxazole Drug Combination
(adverse effects)
- Urinary Tract Infections
(drug therapy)
|